^
Association details:
| Biomarker: | B2M mutation + MSI-H/dMMR |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
B2M and JAK1/2–mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy
Excerpt:
All patients enrolled in this study received at least 2 courses of anti-PD-1 therapy with or without chemotherapy. All of the 35 patients were MSI-H/dMMR and received anti-PD-1 therapy...the better clinical response to anti-PD-1 therapy was also observed in patients with B2M or JAK1/2 mutation type (P=0.035...
DOI:
10.1097/CJI.0000000000000417
